Targeting a key factor in pancreatic cancer treatment resistance
Official title: Targeting HNF1A-mediated therapeutic resistance in pancreatic ductal adenocarcinoma
Funded at Roswell Park Cancer Institute Corp · NIH-11009521 · Data updated 2026-11-12
This study is looking at a tough type of pancreatic cancer and testing a new approach to make current treatments work better by blocking a specific protein, which could help improve outcomes for patients like you.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | February 3, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $518,878 |
| NIH project number | 5R37CA275961-03 |
| Project ID | NIH-11009521 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those who have shown resistance to current therapies.
✕Less likely to help
Patients with other types of cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDA), a highly aggressive cancer with low survival rates. It investigates the role of HNF1A, a transcription factor that contributes to the resistance of pancreatic cancer stem cells to therapies. By using BET-inhibitors to block HNF1A, the research aims to enhance the effectiveness of existing treatments targeting KRAS and its pathways. Patients may benefit from new therapeutic strategies that could improve treatment outcomes for this challenging cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates.
How similar studies have gone: Other research has shown promise in targeting similar pathways in cancer treatment, indicating that this approach may lead to significant advancements.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Abel, Ethan Vincent — Roswell Park Cancer Institute Corp
- Study coordinator: Abel, Ethan Vincent
Related research
Other NIH-funded projects on the same topics.
-
Fibrin-rich tumor stroma as a new driver of immune response in pancreatic cancer
This grant explores how fibrin-involved tumor surroundings in pancreatic cancer might affect immune therapy, with the goal of making treatments work better for patients.
-
TREM2+ macrophages and liver metastases in pancreatic cancer
Researchers are studying immune cells in liver metastases from pancreatic cancer to understand how they influence the cancer’s spread and more effective treatments.
-
Protein S could slow pancreatic cancer and blood clots
A potential treatment study looks at restoring a natural blood protein, Protein S, to help people with pancreatic cancer by slowing tumor growth and reducing dangerous clots.
-
In vivo B7-H3 CAR-T cells for pancreatic cancer therapy
A patient-friendly look at a new approach that aims to produce CAR-T cells directly inside the body to target pancreatic cancer.
-
Metabolic changes in pancreatic cancer when treated with crisantaspase
Aims to understand how pancreatic cancer cells adapt their metabolism when treated with crisantaspase to inform better treatment strategies for patients.
-
New combination therapy for pancreatic cancer in animals
A new therapy designed to weaken the tumor’s protective surroundings and boost treatment effects in pancreatic cancer models.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.